Follow
Elie Ritch
Elie Ritch
University of British Columbia
Verified email at prostatecentre.com
Title
Cited by
Cited by
Year
Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer
G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ...
European urology 75 (4), 667-675, 2019
1102019
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerctDNA Alterations in Metastatic Bladder Cancer
G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ...
Clinical Cancer Research 23 (21), 6487-6497, 2017
1002017
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerctDNA-Based Assessment of MMRd Prostate Cancer
E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ...
Clinical Cancer Research 26 (5), 1114-1125, 2020
432020
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ...
Nature communications 12 (1), 1-12, 2021
382021
Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer
C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ...
European urology 78 (6), 834-844, 2020
312020
Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma
ECP Chedgy, G Vandekerkhove, C Herberts, M Annala, AJ Donoghue, ...
The Journal of pathology 246 (2), 244-253, 2018
282018
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionBRCA2, ATM, and CDK12 in Prostate Cancer
E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ...
Clinical Cancer Research 27 (6), 1650-1662, 2021
232021
Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA
E Ritch, AW Wyatt
Urologic Oncology: Seminars and Original Investigations 36 (8), 380-384, 2018
152018
Enhancing knowledge discovery from cancer genomics data with Galaxy
MA Albuquerque, BM Grande, EJ Ritch, P Pararajalingam, S Jessa, ...
Giga Science 6 (5), gix015, 2017
52017
Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer
G Kumar, E Ritch, HZ Oo, CK Wang, D Tortora, D Thaper, I Moskalev, ...
Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020
12020
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ...
Nature, 1-10, 2022
2022
Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing
C Herberts, M Annala, J Sipola, SW Ng, XE Chen, A Nurminen, ...
Cancer Research 82 (12_Supplement), 3625-3625, 2022
2022
Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer
E Warner, K Van der Eecken, AJ Murtha, EM Kwan, SW Ng, XE Chen, ...
Cancer Research 82 (12_Supplement), 41-41, 2022
2022
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer
NM Fonseca, K Van der Eecken, C Herberts, S Verbeke, SWS Ng, ...
JCO Precision Oncology 6, e2100543, 2022
2022
Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy
JVW Bacon, DC Müller, E Ritch, M Annala, SG Dugas, C Herberts, ...
European Urology Oncology, 2021
2021
Somatic features of response and relapse in non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin
DC Muller, JVW Bacon, E Ritch, SG Dugas, G Vandekerkhove, M Annala, ...
EUROPEAN UROLOGY 79, S617-S617, 2021
2021
Genomic features of lung-recurrent hormone sensitive prostate cancer
K Van der Eecken, N Fonseca, C Herberts, S Verbeke, S Ng, N Lumen, ...
Belgian Week of Pathology, 2021
2021
Regulation of PPARγ expression in luminal muscle invasive bladder cancer
D Tortora, R Morgan, G Kumar, E Ritch, B McConeghy, S Sinha, ...
Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020
2020
Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA
CM Herberts, AJ Murtha, S Fu, G Wang, E Schonlau, A Gleave, S Yip, ...
CLINICAL CANCER RESEARCH 26 (11), 46-47, 2020
2020
Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA
CM Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, A Gleave, S Yip, ...
Clinical Cancer Research 26 (11_Supplement), A24-A24, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–20